Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

57.33 +1.71 (+3.07%)
Streaming Delayed Price Updated: 11:55 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,163,250
Open 57.14
Bid (Size) 57.32 (3)
Ask (Size) 57.34 (6)
Prev. Close 55.62
Today's Range 56.63 - 57.44
52wk Range 45.05 - 138.22
Shares Outstanding N/A
Dividend Yield 3.83%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study
Via Stocktwits
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients. 
Via Benzinga

Performance

YTD
-34.5%
-34.5%
1 Month
+6.7%
+6.7%
3 Month
-25.6%
-25.6%
6 Month
-28.5%
-28.5%
1 Year
-58.1%
-58.1%

More News

Read More
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap
Via The Motley Fool
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report
Via Stocktwits
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
Via The Motley Fool
What's Going On With Novo Nordisk Shares Monday?
Via Benzinga
Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact
Via Benzinga
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Via MarketMinute
Topics Economy Intellectual Property
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
Why Novo Nordisk Stock Popped Today
Via The Motley Fool
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks
Via Benzinga
NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
How Do Investors Really Feel About Novo Nordisk?
Via Benzinga
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
From Faruqi & Faruqi LLP
Via GlobeNewswire
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
Via The Motley Fool
Topics ETFs
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 57.33
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/16/25 11:55 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.